For Immediate Release
Chicago, IL – March 28, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (
GOOGL Quick Quote GOOGL - Free Report) , Abbott Laboratories ( ABT Quick Quote ABT - Free Report) , The Charles Schwab Corp. ( SCHW Quick Quote SCHW - Free Report) , Canadian National Railway Company ( CNI Quick Quote CNI - Free Report) and Air Products and Chemicals, Inc. ( APD Quick Quote APD - Free Report) . Here are highlights from Friday’s Analyst Blog: Top Research Reports for Alphabet, Abbott and Charles Schwab
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc., Abbott Laboratories and The Charles Schwab Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today's research reports here >>>
Alphabet have outperformed the Zacks Internet - Services industry over the past year (+39.8% vs. +17.8%) on the back of solid momentum across search, advertising, cloud and YouTube businesses. Further, the growing proliferation of consumer online activities and rising advertiser spending remained tailwinds.
Alphabet's robust cloud division continues to be the key catalyst. Moreover, expanding data centers will continue to bolster its presence in the cloud space. Further, major updates in its search segment are enhancing the search results. Moreover, Google's mobile search is constantly gaining solid traction. Also, strong focus on AI techniques and the home automation space should aid business growth in the long term. Yet, its growing litigation issues remain concerns.
) read the full research report on Alphabet here >>> Abbott shares have declined -2% over the past year against the Zacks Medical - Products industry's decline of -7.3%. However, Abbott did post better-than-expected earnings and revenue numbers for the fourth quarter of 2021. Barring Neuromodulation (a 7.5% year-over-year decline), the company registered organic sales growth across all its operating segments.
The Zacks analyst believes that COVID-19 testing-related sales were driven by demand for BinaxNOW, Panbio and ID NOW rapid testing platforms. Within the Diabetes Care business, the company has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. Within Adult Nutrition, the company gained from the strong performance of Ensure and Glucerna brands.
However, the company's projection indicates a fall in COVID testing revenues through the later part of 2022. Year-over-year drop in Neuromodulation sales was concerning.
) read the full research report on Abbott here >>>
Charles Schwab have outperformed the Zacks Financial - Investment Bank industry over the past year (+39.3% vs. +7.6%). The Zacks analyst believes that strategic acquisitions have reinforced Schwab's position as a leading brokerage player. The same will likely be accretive to earnings. Offering commission-free trading has led to a rise in client assets and brokerage accounts, thereby improving trading revenues.
Schwab's efficient capital deployments reflect a solid balance sheet position, through which it will enhance shareholder value. However, despite expectations of a few rate hikes, relatively lower interest rates will likely keep hurting margins in the near term. Elevated operating expenses might hamper the company's bottom-line growth to an extent.
) read the full research report on Charles Schwab here >>> Other noteworthy reports we are featuring today include Canadian National Railway Company and Air Products and Chemicals, Inc. Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press relea https://www.zacks.com/performance